NeoImmuneTech, Inc. (NIT) is led by seasoned executives relentlessly pursuing the development of novel drug in immuno-oncology.

Se Hwan Yang, Ph.D. - President / Chief Executive Officer
Dr. Se Hwan Yang founded NeoImmuneTech in January 2014. Dr. Yang has created several intellectual-property protected inventions, including the hyFc® platform technology and drug candidate. Prior to his position at NIT, Dr. Yang was Genexine’s Head of Research Institute and Business division from 2007 to 2014 and has served as a BOD member of Genexine. He received his Ph.D. from Pohang University of Science and Technology and has over 20 years of experiences of research, product development and business in life sciences, including molecular biology, immunology and protein engineering.


Clinical Division
Byung Ha Lee

Chief Scientific Officer
/ Head of Clinical Division

Hye Jeong

Medical Director of Drug
Safety and Pharmacovigilance

Sara Ferrando Martinez

Head of Clinical Sciences

Mary E. Muench-Holum

Head of Clinical Operations

Quality Assurance Division
Jiyoung Joo

Chief Quality Officer
/ Head of QA Division

Hee Yong Jeong

Executive Director

Richard Sloma

Senior Director of
Clinical QA

CMC Division
Eun Jeong Bae

Senior Director
/ Head of CMC Division

Regulatory Affairs Division
Jin Hee Kang

Chief Regulatory Officer
/ Head of RA Division

Alicia Staz

RA Director

Eui Sok Jung

RA Director

Research Institute
Donghoon Choi

Chief Technology Officer
/ Head of Research Institute

S&P Division
Daniel Rho

Director / Director of
Strategy & Planning

Hyun Jee Kim

Executive Director

Finance Division
Tae Woo Kim

Chief Financial Officer
/ Head of Finance Division

Investor Relations Division
Hayoung Lee

Chief Investor Relations Officer
/ Head of IR Division

Management Division
Gene Namgoong

Chief Operating Officer
/ Head of Management Division

Dana Wyche

IT Director

Soon Phil Lee

Senior Director
/ Management